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Introduction
The programmed cell death 1 (PD-1) receptor, a transmembrane protein and member of the B7 family, plays a critical role in T cell regulation [1] . PD-1 is expressed on T cells, where its expression increases within the first 24 h of T cell activation and decreases with antigen clearance [2] [3] [4] . Upon ligation of PD-1 by its ligands (PD-L1/B7-H1 and PD-L2/B7-DC), T cell responses are down-regulated [5, 6] . PD-1 ligation leads to inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, resulting in reduced Akt (protein kinase B) phosphorylation and reduced expression of transcription factors GATA-3, T-bet and Eomes [7, 8] . The overall effect of PD-1 ligation is decreased T cell activation and cytokine production [9] [10] [11] [12] . The clinical relevance of PD-1 in immune regulation is evidenced by the recent success of PD-1 blockade in the treatment of certain endstage cancers, leading to reduced tumour burden and enhanced anti-tumour immunity in a considerable number of patients [13, 14] . Conversely, in inflammatory conditions it has been documented that disruption of the PD-1 gene (pdcd1) in mice leads to lupus-like syndrome, proliferative arthritis, diabetes, autoimmune cardiomyopathy and increased susceptibility to collagen-induced arthritis (CIA) [15] [16] [17] [18] [19] [20] . In humans, polymorphisms in the PDCD1 gene have been associated with susceptibility to rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and type 1 diabetes mellitus [21] [22] [23] [24] [25] .
Several investigators have shown that frequencies of PD-1 1 CD4
1 T cells are increased in RA synovial fluid compared to RA peripheral blood (PB) and healthy control (HC) PB [20, 26, 27] . However, despite high levels of this inhibitory receptor at the site of inflammation, the immune system seems unable to regulate persistent T cell activation and cytokine production. This poses the question as to whether the PD-1 pathway is impaired during inflammation. An indication of a defective PD-1 pathway in RA comes from a study indicating that RA synovial fluid (SF) CD4 1 T cells show reduced PD-1-mediated inhibition compared to RA PB cells [20] . This suggests that under conditions of chronic inflammation the PD-1 pathway is modulated. Thus far, little is known regarding the PD-1/ PD-L1 pathway in the context of psoriatic arthritis (PsA). PsA and RA, while sharing a number of common pathological features, are two distinct diseases with serological, genetic and radiological differences [28] . Here we determined the expression of PD-1 on T cells from PB and SF of patients with RA or PsA, and investigated how inflammatory mediators associated with RA and PsA affect PD-1-mediated T cell suppression. Our data indicate that CD4
1
T cells from patients with RA and PsA are compromised in their PD-1-mediated inhibition and reveal a potential role for soluble PD-1 (sPD-1) in the aberrant PD-1-mediated regulation in these diseases.
Materials and methods

Patients and healthy volunteers
Heparinized PB and matched SF samples were obtained from patients with RA and PsA recruited from the rheumatology out-patient clinic at Guy's and St Thomas' Hospital NHS Trust (London, UK). Information on clinical and demographic parameters is provided in Supporting information, Table 1 . HC subjects were recruited from among local student and staff volunteers. Written informed consent was received from all participants. PBMC, SFMC and cell subset isolation PB mononuclear cells (PBMC) and SF mononuclear cells (SFMC) were isolated by Lymphoprep TM (Axis-Schield, Oslo, Norway) density-gradient centrifugation. Cell subsets were isolated by magnetic separation (Miltenyi Biotech, Bergisch Gladbach, Germany and Dynabeads Thermofisher, Paisley, UK) and purity was determined by flow cytometry. CD4
1 T cells (purity range 95-99%) were isolated by negative isolation from PBMC or SFMC or from the CD14-depleted cell fractions following the manufacturers' instructions. CD14 1 monocytes (purity range 96-98%) were selected positively using CD14 MicroBeads (Miltenyi Biotec).
Cell culture
Cell subsets were cultured for 5 days in culture medium (RPMI-1640; GIBCO, Paisley, UK), supplemented with 1% penicillin/streptomycin, 1% L-glutamine (GIBCO) and 10% heat-inactivated fetal calf serum (GIBCO) and maintained at 378C and 5% CO 2 atmosphere. Cells were stimulated with either plate-bound anti-CD3 monoclonal antibody (mAb) (OKT3; Janssen-Cilag Ltd, High Wycombe, UK) (1Á5 mg/ ml) in CD4 1 T cell only cultures or with soluble anti-CD3 mAb (OKT3; Janssen-Cilag Ltd) (100 ng/ml) in CD4 Chalfont, UK) and T cell proliferation was assessed after 18 h (on day 5) using a Topcount scintillation counter (Perkin Elmer, Cambridge, UK). Proliferation was determined and expressed as counts per minute (cpm) and as suppression of T cell proliferation (%) according to the following formula: [(medium only condition 2 PD-L1fc condition)/medium only condition] 3 100.
Detection of soluble cytokines and soluble PD-1
CD4
1 T cell culture supernatants were collected at day 5
and stored at 2808C. IFN-g levels were determined by enzyme-linked immunosorbent assay (ELISA) using the ELISA MAX TM standard set (Biolegend). Levels of sPD-1
were determined by human PD-1 DuoSet ELISA (R&D Systems). Serum samples from HC donors and serum and paired cell-free SF samples from patients with OA, RA or PsA were collected and stored at 2808C until analysed by ELISA (for sPD-1; R&D Systems) or Bio-Plex Pro TM (for TNFa, IL-6 and IL-1b; Bio-Rad Laboratories) on the Luminex FlexMap 3D platform (Luminex Corporation, Austin, TX, USA). All assays were performed according to the manufacturers' protocols.
RNA extraction and real-time-quantitative polymerase chain reaction (RT-qPCR)
Total RNA was isolated using the ReliaPrep TM RNA cell
Miniprep System (Promega, Southampton, UK) according to the manufacturer's protocol. cDNA synthesis was performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) and mRNA expression of PD-1Dex3 was determined using the Sensi- 
Statistical analysis
Significance testing was performed with GraphPad Prism software (version 7; GraphPad, La Jolla, CA, USA) using the appropriate statistical tests, as indicated in the figure legends.
Results
PD-1
1 T cell frequencies are increased in RA and PsA synovial fluid compared to peripheral blood PD-1 ligation reduces proliferation of CD4 1 T cells from healthy donors, but not CD4
1 T cells from patients with RA or PsA
To investigate whether the PD-1 expression is functional in RA and PsA, we set up a PD-1 ligation assay using anti-CD3 and PD-L1fc (or IgG1fc as control)-coated plates, based on previously described protocols [9, 29, 30] . As expected, PD-1 ligation resulted in a significant and dose-dependent reduction of healthy control PB-derived CD4 1 T cell proliferation, while no effect was observed in the presence of IgG1fc control (Fig. 2a,b) . IFN-g production was also inhibited in a PD-L1fc dose-dependent fashion (Supporting information, Fig. S1a ). We then compared PD-1 ligation of PB-derived CD4 1 T cells from healthy donors and patients with RA in parallel experiments. In contrast to the suppressive effects on T cell proliferation observed upon PD-1 ligation of CD4 1 T cells from healthy donors, CD4 1 T cells from patients with RA appeared to be resistant to PD-1-mediated suppression of T cell proliferation (Fig. 2c,d ). Next, we cultured CD4 1 T cells from the blood and synovial fluid from patients with RA and PsA with increasing doses of plate-bound PD-L1fc. Even at the highest dose of PD-L1fc (5 mg/ml) we did not detect a decrease in T cell proliferation upon PD-1 ligation (Fig. 2e,f) . Similarly, when RA and PsA cell culture supernatants were tested for IFN-g production, we could not detect a consistent decrease in the levels of IFN-g (Supporting information, TNFa, IL-6 and IL-1b counteract PD-1-mediated suppression of CD4 1 T cell proliferation
Because RA and PsA CD4 1 T cells, especially those from the synovial fluid, are derived from a proinflammatory environment, we sought to examine how inflammatory cytokines may influence PD-1-mediated T cell suppression. First, we determined the levels of TNFa, IL-6 and IL-1b in RA and PsA-derived sera and paired SF, compared to healthy serum and serum and SF from disease control patients with osteoarthritis (OA). Increased levels of all three cytokines were detected in both RA and PsA SF when compared to HC serum or OA SF (Fig. 3a,b) . These data confirm the inflammatory nature of SF in both RA and PsA. In the analysed RA and PsA sera, we only found mild increases of TNFa and IL-6 compared to healthy or OA control serum. Next, we assessed whether the presence of TNFa, IL-6 or IL-1b had a functional impact on PD-1-mediated suppression of CD4 1 T cell proliferation. HC CD4 1 T cells were cultured with increasing concentrations of PD-L1fc (0, 0Á1 and 1 mg/ml) in the absence or presence of TNFa, IL-6 or IL-1b (10 ng/ml). To block the effect of the cytokines, the anti-TNFa drug adalimumab, anti-IL-6R drug tocilizumab or anti-IL-1b mAb (1 mg/ml) were added at the beginning of the culture where indicated. Addition of each individual cytokine was able to abrogate the suppressive effects of PD-1 ligation on CD4 1 T cell proliferation at both 0Á1 and 1 mg/ml PD-L1 concentrations (Fig. 3c ). In each sample tested, adalimumab, tocilizumab and anti-IL-1b mAb were able to reverse these cytokine-mediated effects completely. Together, these data indicate that the RA-and PsA-associated inflammatory cytokines TNFa, IL-6 and IL-1b can counteract the suppressive effects of PD-1 ligation on CD4 1 T cells, at least in vitro.
Soluble PD-1 (sPD-1) is induced in vitro by TNFa and IL-6 in HC CD4 1 T cell cultures and can be detected in serum and SF of both RA and PsA patients
Having demonstrated that TNFa, IL-6 and IL-1b can be detected in RA and PsA patients and that each of these and SF cell populations. Data were analysed by Wilcoxon matched-pairs signed-rank test. *P < 0Á05, **P < 0Á01 and ***P < 0Á001. Isotype control staining showed a similar result to fluorescence minus 1 (FMO) staining (Supporting information, Fig. S5 ). cytokines abrogates PD-L1fc activity in vitro, we sought to identify a possible underlying mechanism. ELISA analysis of HC CD4 1 T cell supernatants from cytokine-stimulated cultures revealed that both TNFa and IL-6 were able to induce sPD-1 compared to medium-only conditions (Fig.  4a,b) . No significant increase in sPD-1 was observed in IL1b-stimulated cultures (Fig. 4c) . This increase in sPD-1 was abrogated in the presence of adalimumab or and IL-1b in paired rheumatoid arthritis (RA) and psoriatic arthritis (PsA) serum/synovial fluid (SF) (n 5 12), in osteoarthritis (OA) (disease control) serum/SF (n 5 3-4) and in HC serum (n 5 7). Wilcoxon's matchedpairs signed-rank test for RA/PsA serum versus RA/PsA SF and MannWhitney test for RA/PsA SF versus HC serum or OA SF. *P < 0Á05, **P < 0Á01 and ***P < 0Á001. (c) Plates were coated with PD-L1fc at the indicated concentrations, and PD-L1-mediated suppression of proliferation by CD4 1 T cells from HC PB was assessed in absence (medium, M) or presence of 10 ng/ml of TNFa (n 5 9), IL-6 (n 5 5) or IL-1b (n 5 6) 6 anti-TNFa (adalimumab; ADA), anti-IL-6R (tocilizumab; TOC) and anti-IL-1b (all at 1 mg/ml). Data in (c) were analysed by Wilcoxon matched-pairs signed-rank test. *P < 0Á05 and **P < 0Á01. tocilizumab. Quantitative PCR analysis of HC CD4 1 T cells from the same TNFa-and IL-6-stimulated cultures revealed increases of the PD-1Dex3 splice variant (Supporting information, Fig. S2 ). These results are in line with a previous study from another group reporting that TNFa promotes sPD-1 expression [31] but also identify IL-6 as an inducer of sPD-1 and PD-1Dex3. In addition, ELISA analysis revealed that sPD-1 was detectable in none of three OA serum and none of four OA SF samples, while it was detected at high levels in 13 of 17 RA and 13 of 18 PsA serum and SF samples (Fig. 4d) . Additionally, cross-sectional analysis of serum and SF from patients with RA or PsA undergoing TNF-inhibitor (TNFi) therapy revealed lower levels of sPD-1 when compared to patients not receiving TNFi therapy (Fig. 4e) . These data show that proinflammatory cytokines such as TNFa and IL-6 can modulate the amount of sPD-1 in vitro and that TNFi therapy might modulate sPD-1 levels in the serum and SF of patients with inflammatory arthritis.
sPD-1 modulates PD-1-mediated suppression of HC CD4
1 T cells and induces proliferation in CD4 1 T cell/CD14
1 monocyte co-cultures
To investigate whether sPD-1 is able to modulate PD-1/ PD-L1 interactions, we first tested if sPD-1fc itself promotes T cell proliferation of anti-CD3 stimulated HC CD4 1 T cells cultured in the absence of PD-L1fc. In these experimental conditions, sPD-1fc did not induce any increase in cell proliferation (Supporting information, Fig.  S3 ), suggesting no direct effect on HC CD4 1 T cells. We then cultured HC CD4 1 T cells in the presence of increasing amounts of PD-L1fc ligand in the absence or presence of sPD-1fc chimera (0Á5 or 1 mg/ml). In PD-L1fc precoated plates, addition of sPD-1fc was able to abrogate the activity of the ligand in a dose-dependent fashion, resulting in less efficient suppression of T cell proliferation when compared to medium only (Fig. 5a,b) . These data indicate that in a CD4 1 T cell-only culture system, sPD-1 is able to modulate negatively an otherwise functional PD-1/PD-L1 interaction.
To investigate further the ability of sPD-1 to modulate the PD-1/PD-L1 interaction, we set up a co-culture system using HC CD4
1 T cells and autologous CD14 1 cells as a source of natural PD-L1. The ability of HC CD14 1 cells to express PD-L1 was tested by flow cytometry by culturing the cells overnight with 10 ng/ml of IFN-g, a known inducer of PD-L1 [27, 32] (Supporting information, Fig.  S4 ). Freshly isolated HC CD4 1 T cells and autologous monocytes were cultured at a 1 : 1 ratio with soluble anti-CD3 mAb (100 ng/ml) in the absence or presence of increasing doses of sPD-1 or IgG1fc control (0Á25, 0Á5 and 1 mg/ml). Addition of sPD-1fc led to a significant dosedependent increase in T cell proliferation compared to control-treated cells (Fig. 5c,d ). These data indicate that soluble PD-1 receptor can modulate PD-1 ligation in both an artificial system (PD-L1fc precoated plates) as well as in a more physiological context (in the presence of PD-L1 1 APC).
Discussion
The present study provides evidence for compromised PD-1 mediated suppression in CD4 1 T cells from patients with RA and PsA. Our study identifies the proinflammatory cytokines TNFa, IL-6 and IL-1b as negative modulators of PD-1-mediated T cell suppression in vitro and demonstrates that sPD-1 is capable of interfering with effective PD-1 ligation. To our knowledge, this is the first study to examine PD-1 function in RA and PsA simultaneously, and to provide evidence that the inflammatory milieu of these two diseases has a role in modulating PD-1 ligation. We show that the frequencies of PD-1 1 cells within CD4 1 and CD8 1 T cell subsets are increased significantly in the synovial fluid from patients with RA or PsA when compared to peripheral blood, thus extending the findings from previous studies focusing only on RA [20, 26, 27, 33] . The increase in the frequencies of PD-1 1 T cells suggests that in RA and PsA PD-1 might have a role in regulating T cell effectors, especially at the site of inflammation. However, despite this increased frequency of PD-1 1 T cells, inflammation persists, suggesting that this pathway is impaired in these diseases. Thus far, only limited data exist regarding PD-1 function in inflammatory arthritis. One study using a PD-L1fc chimera demonstrated that PD-1 ligation inhibited cell proliferation and IFN-g production by CD4
1 T cells from peripheral blood of RA patients, but that synovial fluid CD4 1 T cells required higher concentrations of PD-L1fc to achieve similar levels of inhibition [20] . The authors speculated that the inflammatory milieu found in the RA joint might be accountable for reduced PD-1-mediated suppression, as they showed that addition of cell-free SF to RA PB CD4 1 T cells modulated PD-1 ligation negatively [20] .
However, no specific mediator of the effect was identified. It has been shown previously that the common gamma chain cytokines IL-2, IL-7 and IL-15, as well as CD28 costimulation, can interfere with PD-1 cross-linking via pSTAT-5 activation [9, 29] . In our study, we show that in both RA and PsA, CD4 1 T cells from the blood and synovial fluid are more resistant to PD-1 ligation in terms of suppression of T cell proliferation and IFN-g production when compared to healthy cells. We show that the proinflammatory cytokines TNFa, IL-6 and IL-1b are found at increased levels in RA and PsA SF, and can reduce PD-1-mediated suppression of proliferation in CD4 1 T cells from healthy donors. Inhibitors of these cytokines can counteract this effect. These findings provide further evidence that the presence of certain proinflammatory cytokines can be critical in determining the outcome of PD-1 engagement during the immune response.
Mechanistically, our data demonstrate that TNFa and IL-6, but not IL-1b, induce the secretion of sPD-1 by CD4
1 T cells, and that sPD-1 levels are increased significantly in the serum and SF of patients with RA or PsA compared to OA. The latter data support and extend two recent studies that showed that sPD-1 can be detected in the serum and SF from patients with RA [27, 34] . In these studies sPD-1 serum levels correlated positively with the Disease Activity Score (DAS28), the presence of rheumatoid factor, and with levels of TNFa in the RA SF but not the serum [27, 34] . Recent studies showed that expression of the PD-1Dex3 variant is observed in T cells from patients with RA, but only minimally in T cells from patients with OA or from HC [27, 31] . PD-1Dex3 is a splice variant of PD-1, which lacks the transmembrane domain and whose putative translational product is a soluble form of PD-1 [34, 35] . It was shown that TNFa, IL-17 and IFN-g can increase PD-1Dex3 splice variant mRNA expression in healthy human CD4 1 T cells [31] . Our data indicate that in addition to those cytokines, sPD-1 protein expression and PD-1Dex3 splice variant mRNA expression can also be regulated by IL-6. Furthermore, preliminary analysis from a cross-sectional investigation of PsA and RA serum and SF suggests that patients treated with TNFi therapy have lower sPD-1 levels compared to patients not treated with TNFi therapy. Further longitudinal studies on patients treated with adalimumab or tocilizumab are required, however, before conclusive statements can be made regarding the effect of biologics on sPD-1 levels. Our data demonstrate that the inflammatory cytokines TNFa and IL-6 can lead to increased levels of PD-1Dex3 splice variant as well as sPD-1. It is possible that a certain amount of PD-1 might also be released from the cell membrane via other mechanisms. The presence of high levels of certain metalloproteinases (MMPs) such as MMP-9 and MMP-13 has been described previously in inflammatory arthritis [36, 37] , and it has been shown recently that expression of the PD-1 ligands PD-L1 and PD-L2 in infant foreskin fibroblasts can be regulated through proteolytic cleavage by MMPs [38] . Future studies may reveal whether such an MMP-mediated proteolytic cleavage may also contribute to generation of soluble PD-1.
Notably, we show, using a recombinant PD-1 chimera, that sPD-1 is functionally able to counteract PD-L1fc-mediated suppression of healthy CD4
1 T cell proliferation, and to enhance CD4 1 T cell proliferation when cocultured with CD14 1 monocytes that can naturally express PD-L1. Importantly, recent studies in autoimmune hepatitis [39] and cutaneous systemic sclerosis [40] support the notion that sPD-1 might interfere with the PD-1 pathway, thereby disrupting T cell regulation. Collectively, our data indicate that CD4 1 T cells from the PB and SF of patients with chronic RA or PsA are more resistant to PD-1-mediated regulation than CD4 1 T cells from healthy individuals. We show that the proinflammatory cytokines TNFa, IL-6 and IL-1b, which are present at increased levels in the inflamed joints of RA and PsA patients, are capable of negatively modulating PD-1 ligation in vitro. Finally, we show that TNFa and IL-6 are capable of inducing sPD-1 in HC CD4 1 T cells and that sPD-1 modulates T cell proliferation by interfering with PD-1 ligation. Thus, our findings provide new evidence that the inflammatory environment of the RA and PsA joint compromises PD-1/PD-L1-mediated T cell regulation.
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